非小细胞肺癌患者外周血ERCC1单核苷酸多态性与顺铂化疗疗效的相关性  

Relationship between SNPs of ERCC1 in peripheral blood of NSCLC and effects of cisplatin-based chemotherapy

作　　者：李晓惠[1] 蒋蔚峰[1] 张贺龙[1] 张菊[2] 

机构地区：[1]第四军医大学唐都医院肿瘤科,陕西西安710038 [2]第四军医大学药学系全军基因诊断技术研究所,陕西西安710033

出　　处：《中华肿瘤防治杂志》2010年第3期169-172,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家高技术发展计划(863)资助(2008AA02Z444)

摘　　要：目的:探讨非小细胞肺癌(NSCLC)患者外周血中ERCC1第118位密码子单核苷酸多态性(SNPs)及与顺铂化疗疗效的相关性。方法:应用荧光偏振(FP)法检测60例NSCLC患者外周血ERCC1118位密码子SNPs,并分析其与顺铂化疗疗效的关系。结果:ERCC1第118位密码子SNPs与NSCLC患者年龄(P=0.25)、性别(P=0.95)、吸烟史(P=0.75)、TNM分期(P=0.45)及组织学类型(P=0.70)无关。GP、NP、DP三种铂类基础化疗方案化疗疗效组间差异无统计学意义,P=0.99。ERCC1第118位密码子C/C基因型组的化疗有效率为48.6%(17/35),而变异型C/T+T/T有效率仅为20%(5/25),χ2=5.27,P=0.02。结论:ERCC1118位密码子SNPs与顺铂化疗疗效相关。OBJECTIVE：To determine the relationship between SNPs of ERCC1 118 codon and the effects of cisplatin-based chemotherapy in non-small cell lung cancer （NSCLC）.METHODS：ERCC1 C118T mutation was determined by the template directed terminator incorporation with fluorescence polarzation assay（TDI-FP）,and the relationship with the effects of cisplatin-based chemotherapy was studied.RESULTS：ERCC1 SNPs did not show any association with patients＇age （P=0.25）,sex （P=0.95）,smoking history （P=0.75）,clinical TNM stages （P=0.45） and histology types （P=0.70）.There was no statistically significant difference among three GP,NP,and DP chemotherapy schemes （P=0.99）.The response rate of cisplatin-based chemotherapy of C/C gene type patients was 48.6%（17/35）,and the response rate of variant form C/T＋T/T patients was 20%（5/25）,and there was a significant difference （χ^2=5.27,P=0.02）.CONCLUSION：The SNPs of ERCC1 118 codon in NSCLC may be related to the response of cisplatin-based chemotherapy.

关 键 词：癌 非小细胞肺 血液 多态性 单核苷酸 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]